Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [619]
News [1052]
Articles [54]
Editorials [2]
Conferences [97]
elearning [5]
Personalising breast cancer therapies
Dr Philip Poortmans - Institut Curie, Paris, France
Personalising breast cancer therapies ( Dr Philip Poortmans - Institut Curie, Paris, France )
23 Mar 2017
Five years of letrozole does not improve disease free survival for pretreated...
Dr Terry Mamounas - UF Health Center, Orlando, USA
Five years of letrozole does not improve disease free survival for pretreated HR positive breast cancer ( Dr Terry Mamounas - UF Health Center, Orlando, USA )
14 Dec 2016
Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer
Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA
Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer ( Dr Mothaffar Rimawi - Baylor College of Medicine, Houston, USA )
13 Dec 2016
Expert discussion on CDK 4/6 inhibition in breast cancer
Prof Richard Finn, Prof Michael Gnant, Dr Mark Harries and Prof Sandra Swain
Expert discussion on CDK 4/6 inhibition in breast cancer ( Prof Richard Finn, Prof Michael Gnant, Dr Mark Harries and Prof Sandra Swain )
12 Dec 2016
Extended adjuvant endrocine therapy with letrozole after aromatase inhibition
Dr Terry Mamounas - UF Health Center, Orlando, USA
Extended adjuvant endrocine therapy with letrozole after aromatase inhibition ( Dr Terry Mamounas - UF Health Center, Orlando, USA )
7 Dec 2016
Experts discuss the latest in prostate cancer treatments and strategies
Dr Elena Verzoni, Prof Pablo José Maroto-Rey, Dr Elzbieta Senkus-Konefka, Dr...
Experts discuss the latest in prostate cancer treatments and strategies ( Dr Elena Verzoni, Prof Pablo José Maroto-Rey, Dr Elzbieta Senkus-Konefka, Dr Simon Crabb )
20 Nov 2016
CDK clinical trial results, benefit, side effects and costs
Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy
CDK clinical trial results, benefit, side effects and costs ( Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy )
26 Oct 2016
Biomarkers of sensitivity and resistance
Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
26 Oct 2016
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
17 Oct 2016
LUME study of nintedanib finds improved PFS, but no overall survival boost
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
LUME study of nintedanib finds improved PFS, but no overall survival boost ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
12 Oct 2016
Monitoring patterns of care in mCRPC patients with the help of the Cancer...
Dr Simon Chowdhury - Guy's Hospital, London, UK
Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
10 Oct 2016
Lurbinectedin in BRCA 1/2 breast cancer
Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation